MD Anderson Cancer Center

Cancer vaccine, NOUS-209 was found to stimulate the immune system and target precancerous cells in Lynch Syndrome according to MD Anderson Cancer center.

MD Anderson and SOPHiA GENETICS announce a partnership focused on data-driven oncology tools for clinical practice.

MD Anderson Cancer Center received more than $29 million from the Cancer Prevention and Research Institute of Texas to support prevention programs, research efforts, and faculty recruitment.

Researchers at The University of Texas MD Anderson Cancer Center shared insights about how the immune system can be trained to improve patient outcomes.

Researchers conducted the largest, most comprehensive molecular analysis of RMC, leading to the identification of TROP2 as a promising therapeutic target.

The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its third annual scientific symposium on October 24.

The global cross-licensing agreement will facilitate work aimed at enhancing the development of inducible switch technologies for cell and gene therapies.

Topics presented at the conference include the tumor microenvironment, metabolic influences, immune effects, and more.

Researchers have developed the first genome-wide CRISPR screening tool for primary human natural killer cells.

A study finds cancer cells break down protective nerve coverings, leading to nerve injury and chronic inflammation.

The MD Anderson Cancer Center was ranked number one in the nation for cancer care in U.S. News & World Report’s 2024-25 "Best Hospitals" survey.

Collaboration will aim to obtain CAP/CLIA certification of organoid-based assay, followed by clinical studies in multiple indications

Researchers found potential biomarkers that can highly predict which patients with stage III melanoma have better outcomes or are at high risk of recurrence.

Studies have suggested that pre-surgical SRT may be comparable to standard post-surgical SRT in patients with resectable brain metastases.

MD Anderson researchers are enhancing CD19 CAR T-cell therapy outcomes in LBCL through precision medicine insights.

Researchers at MD Anderson Cancer Center have identified a novel target for high-risk multiple myeloma.

Lung cancer patients with high TTF-1 expression had improved survival outcomes following treatment with the KRAS inhibitor, sotorasib.

CPRIT awards over $21 million to MD Anderson for cancer research and faculty recruitment.

Historic donation unites two renowned institutions under one new world-class center created to end childhood cancer

Results from the first-in-human phase I trial were presented at the 2025 AACR Annual Meeting.

A phase 1 trial demonstrated that AFM13-NK cells are safe and highly effective in heavily pretreated patients with lymphomas.

Lung cancer clinician and prevention expert recognized for their achievements in advancing cancer care and research.

MD Anderson was awarded nearly $23 million from the CPRIT for cancer research and faculty recruitment.

The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a collaboration dedicated to pediatric cancer care.

The institute builds upon institutional expertise to develop and advance impactful cell therapies for cancer, autoimmune conditions and infections.

The nation’s top-ranked UT MD Anderson Cancer Center and flagship UT Austin to build new hospitals as part of project.

The University of Texas MD Anderson Cancer Center today announced that Christopher Flowers, MD, an internationally recognized physician-scientist and leader in oncology, has been selected as Division Head of Cancer Medicine after a competitive national search.